Major Customers, Partnerships and Strategic Alliances (Tables)

3 Months Ended

Mar. 31, 2019

Bioverativ Inc [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenues Recognized under Agreement

Revenues recognized under the agreement for the three months ended March 31, 2019 and 2018 were as follows (in thousands):

	Three Months Ended
	March 31,
	2019		2018
Revenue related to Sanofi agreement:
Recognition of upfront fee	$	752	$	1,154
Research services		1,197		3,228
Total	$	1,949	$	4,382